Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 1 institution in 1 country.
Priscila de Souza FurtadoLABHEx, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, lha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-5265-5493
Gil Mendes VianaLabTIF, Departamento de Farmacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-1742-8594
Alana Agnes Silva Camargo de OliveiraLABHEx, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, lha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-2471-3254
Vitor Won-Held RabeloInstituto de Biodiversidade e Sustentabilidade NUPEM, Universidade Federal do Rio de Janeiro CEP 27965-045, Macaé, RJ, Brazil.ORCID 0000-0001-5303-6814
Ingryd Wenderroschy CerqueiraInstituto de Biodiversidade e Sustentabilidade NUPEM, Universidade Federal do Rio de Janeiro CEP 27965-045, Macaé, RJ, Brazil.
Caroline Reis Santiago PaschoalLABHEx, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, lha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-0274-4113
Thiago da Silva HonorioLabTIF, Departamento de Farmacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-3772-7225
Alice SimonLabTIF, Departamento de Farmacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-4673-6182
Carlos Rangel RodriguesDepartamento de Farmacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, ModMolQSAR, Ilha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0001-8453-7654
Paula Alvarez AbreuInstituto de Biodiversidade e Sustentabilidade NUPEM, Universidade Federal do Rio de Janeiro CEP 27965-045, Macaé, RJ, Brazil.ORCID 0000-0003-2204-3012
Lucio Mendes CabralLabTIF, Departamento de Farmacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-4550-5729
Plínio Cunha SathlerLABHEx, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, lha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-1203-3179
Universidade Federal do Rio de Janeiro · BR
Funding
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) 001
6 · The paper itself
Abstract
introductionThrombotic disorders are among the leading causes of morbidity and mortality worldwide. Drugs used in the prevention and treatment of atherothrombosis have pharmacokinetic limitations and adverse effects such as hemorrhagic conditions, highlighting the importance of developing more effective antiplatelet agents.
methodsIn this work, we synthesized
resultsThe synthesized derivatives exhibited a selective inhibitory profile against platelet aggregation induced by arachidonic acid (AA)
conclusionTherefore, these results demonstrated that N,N'-disubstituted ureas are promising candidates for the development of novel antiplatelet agents.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.